Bayer acquires Attralus’ cardiac amyloidosis imaging agents

The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology

Biocon completes Rs. 4,150 crore equity fundraise through QIP

The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited

Vivere Oncotherapies secures more than $10M to tackle hard-to-treat ‘cold’ tumors

Lantern Pharma launches AI Center of Excellence in Bengaluru to scale precision drug discovery globally

Enginzyme and AGC unveil scalable process for key mRNA ingredient at Berlin Conference

BD announces $110 million investment in Nebraska to expand prefillable syringe production

The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products

Teva’s AJOVY gains spotlight as first preventive migraine treatment for kids

The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms

ISVIR 2026 showcases cutting-edge interventional radiology in India

Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine

Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents

The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics

US healthcare costs spark push for Ayurveda integration